Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18237239 | COMMON LIGHT CHAIN MOUSE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17503057 | ANTI-POLYETHYLENE GLYCOL (PEG) ANTIBODY MOUSE MODEL FOR RIGOROUS ASSESSMENT OF PEG-BASED THERAPIES: ADJUVANT-FREE INDUCTION MODEL | Final Rejection | Northwestern University |
| 17707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 16332555 | GENOME EDITED PRIMARY B CELL AND METHODS OF MAKING AND USING | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18457951 | NEW OPTOGENETIC TOOL | Non-Final OA | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. |
| 18352622 | NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING IMMORTALIZED LYMPHOBLASTOID CELL LINES TO INDUCED PLURIPOTENT STEM CELLS | Non-Final OA | Cedars-Sinai Medical Center |
| 16906531 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | Non-Final OA | Merus N.V. |
| 18514227 | MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY | Non-Final OA | HIBM Research Group, Inc. |
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 18287155 | USE OF APOPTOSIS INHIBITORS FOR COLD STORAGE OF BLOOD PLATELETS | Non-Final OA | ZENTRUM FÜR KLINISCHE TRANSFUSIONSMEDIZIN TÜBINGEN GGMBH (ZKT) |
| 17478615 | MODIFIED CELLS AND METHODS OF THERAPY | Non-Final OA | The United States of America, as represented by the Secretary, Department of Health and Human Servic |
| 18120301 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS | Non-Final OA | Children's Medical Center Corporation |
| 18030973 | METHOD FOR PREPARING TRANSGENIC NON-HUMAN ANIMAL HAVING GENOME INCLUDING HUMANIZED IMMUNOGLOBULIN GENE LOCUS | Non-Final OA | HUMAB CO., LTD. |
| 17816608 | HUMANIZED TRANSGENIC ANIMAL | Final Rejection | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 17767803 | VARIANT IGF2 CONSTRUCTS | Non-Final OA | Amicus Therapeutics, Inc. |
| 17822240 | COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME | Final Rejection | Poseida Therapeutics, Inc. |
| 17624123 | RECOMBINANT SIALIDASES AND METHODS OF USING THE SAME | Non-Final OA | Palleon Pharmaceuticals Inc. |
| 16604120 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | Final Rejection | GENOME RESEARCH LIMITED |
| 18061197 | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | Final Rejection | BioAtla, Inc. |
| 16264095 | AAV-BASED GENE THERAPY FOR GLAUCOMA | Final Rejection | The Provost, Fellows, Scholars and other Members of Board of Trinity College Dublin |
| 17436380 | IMMUNOGENIC FORMULATIONS FOR TREATING CANCER | Final Rejection | UNIVERSIDAD DE CHILE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy